Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
11.77
USD
|
+4.25%
|
|
+10.78%
|
+4.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
62.47
|
231.6
|
182
|
113.8
|
202.9
|
232.6
|
-
|
-
|
Enterprise Value (EV)
1 |
62.47
|
231.6
|
182
|
113.8
|
202.9
|
232.6
|
232.6
|
232.6
|
P/E ratio
|
-7.73
x
|
-17
x
|
-5.43
x
|
-4.17
x
|
-6.74
x
|
-5.36
x
|
-6.02
x
|
-6.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
21,206
x
|
1,006
x
|
304
x
|
1,309
x
|
6,231
x
|
4,045
x
|
3,909
x
|
EV / Revenue
|
-
|
21,206
x
|
1,006
x
|
304
x
|
1,309
x
|
6,231
x
|
4,045
x
|
3,909
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-4,122,349
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,771
|
13,448
|
17,843
|
17,946
|
18,022
|
19,761
|
-
|
-
|
Reference price
2 |
5.800
|
17.22
|
10.20
|
6.340
|
11.26
|
11.77
|
11.77
|
11.77
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0109
|
0.181
|
0.374
|
0.155
|
0.0373
|
0.0575
|
0.0595
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.756
|
-12.23
|
-29.15
|
-25.95
|
-29.74
|
-41.27
|
-39.34
|
-40.24
|
Operating Margin
|
-
|
-111,975.09%
|
-16,106.63%
|
-6,938.77%
|
-19,187.74%
|
-110,549.16%
|
-68,418.26%
|
-67,631.09%
|
Earnings before Tax (EBT)
1 |
-7.678
|
-12.1
|
-30.34
|
-27.3
|
-30.01
|
-41.21
|
-39.4
|
-40.3
|
Net income
1 |
-7.678
|
-12.1
|
-30.34
|
-27.3
|
-30.01
|
-41.21
|
-39.4
|
-40.3
|
Net margin
|
-
|
-110,798.17%
|
-16,762.43%
|
-7,299.2%
|
-19,360%
|
-110,404.5%
|
-68,519.13%
|
-67,728.57%
|
EPS
2 |
-0.7500
|
-1.010
|
-1.880
|
-1.520
|
-1.670
|
-2.197
|
-1.955
|
-1.865
|
Free Cash Flow
|
-
|
-
|
-44.15
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-24,392.27%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.014
|
0.163
|
0.163
|
0.016
|
0.098
|
0.097
|
-
|
0.046
|
0.043
|
0.028
|
0.028
|
0.028
|
0.028
|
0.028
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.021
|
-9.03
|
-6.478
|
-6.388
|
-7.443
|
-5.642
|
-
|
-6.411
|
-8.528
|
-8.379
|
-9.34
|
-10.41
|
-11.62
|
-12.96
|
Operating Margin
|
-64,435.71%
|
-5,539.88%
|
-3,974.23%
|
-39,925%
|
-7,594.9%
|
-5,816.49%
|
-
|
-13,936.96%
|
-19,832.56%
|
-29,925%
|
-33,357.14%
|
-37,192.86%
|
-41,489.29%
|
-46,300%
|
Earnings before Tax (EBT)
1 |
-9.458
|
-9.671
|
-6.903
|
-6.838
|
-7.725
|
-5.833
|
-
|
-6.501
|
-8.563
|
-8.408
|
-9.369
|
-10.44
|
-11.65
|
-12.99
|
Net income
1 |
-9.458
|
-9.671
|
-6.903
|
-6.838
|
-7.725
|
-5.833
|
-6.536
|
-6.501
|
-8.563
|
-8.408
|
-9.644
|
-10.88
|
-12.24
|
-13.68
|
Net margin
|
-67,557.14%
|
-5,933.13%
|
-4,234.97%
|
-42,737.5%
|
-7,882.65%
|
-6,013.4%
|
-
|
-14,132.61%
|
-19,913.95%
|
-30,028.57%
|
-34,444.64%
|
-38,862.5%
|
-43,725%
|
-48,862.5%
|
EPS
2 |
-0.5500
|
-0.5500
|
-0.3900
|
-0.3800
|
-0.4300
|
-0.3200
|
-0.3600
|
-0.3600
|
-0.4800
|
-0.4700
|
-0.5350
|
-0.5950
|
-0.6600
|
-0.6550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/3/22
|
5/5/22
|
8/3/22
|
11/2/22
|
3/2/23
|
5/3/23
|
8/7/23
|
11/1/23
|
3/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-44.2
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
15
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
8,287.29%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
11.77
USD Average target price
19.67
USD Spread / Average Target +67.09% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.53% | 223M | | -2.63% | 103B | | +1.62% | 95.28B | | +1.46% | 22.15B | | -16.67% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -13.21% | 16.05B | | +5.41% | 13.68B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|